Ganaxolone.
Virinder Nohria, Earl Giller
Index: Neurotherapeutics 4(1) , 102-5, (2007)
Full Text: HTML
Abstract
Ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) (GNX) is the 3beta-methylated synthetic analog of allopregnanolone; it belongs to a class of compounds referred to as neurosteroids. GNX is an allosteric modulator of GABA(A) receptors acting through binding sites which are distinct from the benzodiazepine binding site. It has activity in a broad range of animal models of epilepsy. GNX has been shown to be well tolerated in adults and children. In early phase II studies, GNX has been shown to have activity in adult patients with partial-onset seizures and epileptic children with history of infantile spasms. It is currently undergoing further development in infants with newly diagnosed infantile spasms, in women with catamenial epilepsy, and in adults with refractory partial-onset seizures.
Related Compounds
Related Articles:
2015-01-22
[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 976-977 , 6-18, (2015)]
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
2005-02-01
[Xenobiotica 35 , 191-210, (2005)]
2015-09-15
[Behav. Brain Res. 291 , 164-71, (2015)]
A potential effect of ganaxolone in an animal model of infantile spasms
2014-11-01
[Epilepsy Res. 108(9) , 1492-500, (2014)]
Anticonvulsant doses of ganaxolone do not compromise motor performance in immature rats.
2010-01-29
[Neurosci. Lett. 469(3) , 396-9, (2010)]